Last reviewed · How we verify

Saxagliptin + Metformin

AstraZeneca · FDA-approved active Small molecule

Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.

At a glance

Generic nameSaxagliptin + Metformin
Also known asBMS-477118, Onglyza
SponsorAstraZeneca
Drug classDPP-4 inhibitor + biguanide combination
TargetDPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Saxagliptin is a DPP-4 inhibitor that prevents the breakdown of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing insulin secretion in response to meals and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose output and increases peripheral glucose uptake and insulin sensitivity. Together, they provide complementary glucose-lowering effects in type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: